Compounds > solifenacin succinate
Page last updated: 2024-09-05

solifenacin succinate and mirabegron

solifenacin succinate has been researched along with mirabegron in 73 studies

Compound Research Comparison

Studies
(solifenacin succinate)		Trials
(solifenacin succinate)		Recent Studies (post-2010)
(solifenacin succinate)		Studies
(mirabegron)		Trials
(mirabegron)		Recent Studies (post-2010) (mirabegron)
522194343558131538

Research

Studies (73)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's50 (68.49)24.3611
2020's23 (31.51)2.80

Authors

AuthorsStudies
Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R1
Andersson, KE1
Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M2
Hagiwara, M; Hasegawa, M; Ishioka, K; Kikuchi, E; Maeda, T; Miyajima, A; Miyazaki, Y; Oya, M; Shinojima, T1
Abrams, P; Kay, R; Martina, R; Ridder, A; van Maanen, R1
de Greef-van der Sandt, I; Dorrepaal, C; Martina, R; Newgreen, D; Ridder, A; Schaddelee, M; van Maanen, R1
Berner, T; Castro-Diaz, D; Kelleher, C; Nitti, VW; Siddiqui, E; Wagg, A1
Athanasiou, S; Cambronero, J; Chapple, C; Drake, MJ; Esen, AA; Herholdt, C; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Saleem, T; Siddiqui, E; Stölzel, M1
Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Grise, P; Hakimi, Z; Hemsted, C; Herschorn, S; Huang, M; MacDiarmid, S; Nazir, J; Saleem, T; Siddiqui, E; Stölzel, M1
Morosetti, C; Vecchioli Scaldazza, C1
Alcántara-Montero, A1
Sidaway, P2
Griebling, TL1
Imamura, T; Ishizuka, O; Minagawa, T; Nagai, T; Nakazawa, M; Ogawa, T; Saito, T; Suzuki, T; Yokoyama, H1
Abrams, P; Kay, R; Kelleher, C; Martan, A; Mincik, I; Newgreen, D; Paireddy, A; Ridder, A; Staskin, D; van Maanen, R1
Cruz, F1
Kinjo, M; Nutahara, K; Sekiguchi, Y; Yoshimura, Y1
Blais, AS; Bolduc, S; Genois, L; Moore, K; Morin, F; Nadeau, G1
Wein, AJ2
Kirby, J; Obloza, A; Toozs-Hobson, P; Yates, D1
Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Herschorn, S; Huang, M; MacDiarmid, S; Siddiqui, E; Stoelzel, M1
Krivoborodov, GG; Tur, EI1
Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R1
Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M1
Itai, S; Iwao, Y; Katakawa, Y; Kimura, SI; Matsuzaki, N; Mimura, H; Murayama, D; Yamamoto, Y1
Devlin, N; Drake, MJ; Hakimi, Z; Herdman, M; Huang, M; MacDiarmid, S; Nazir, J; Pavesi, M; Siddiqui, E1
Falconer, C; Hakimi, Z; Herschorn, S; Kelleher, C; Mueller, ER; Paireddy, A; Ridder, A; Robinson, D; Staskin, D; Stoelzel, M; van Maanen, R; Wang, J1
Hodgkinson, L1
Choudhury, N; Drake, MJ; Gibson, W; Huang, M; MacDiarmid, S; Siddiqui, E; Stölzel, M1
Apostolidis, A1
Baltogiannis, D; Dimitriadis, F; Filiponi, M; Giannakis, J; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A1
Benedetti Panici, P; D'Oria, O; Faiano, P; Muzii, L; Schiavi, MC; Zullo, MA1
Chang, HM; Chang, YC; Chen, HL; Chen, TC; Huang, WH; Juan, YS; Lee, HY; Pan, HF; Wang, YL; Wu, CM1
Chapple, CR; Frankel, JM; Gratzke, C; Herschorn, S; Paireddy, A; Ridder, AM; Robinson, D; Stoelzel, M; van Maanen, R; Weber, MA; White, WB1
Chang, SL; Dupree, JM; Kirk, PS; Modi, PK; Singer, EA; Wang, Y1
Kuo, HC; Wang, CC1
Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ1
Staskin, DR1
Kim, JH; Lee, SR; Park, BW1
Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z1
Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Rechberger, T; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ1
Gratzke, C; Siddiqui, E1
Bogusiewicz, M; Kulik-Rechberger, B; Miotla, P; Rechberger, E; Rechberger, T; Wrobel, A; Zietek, A1
Almeida, FG; Bernardo, WM; Sacomani, CAR; Silvinato, A1
Gao, Z; Zhou, Z1
Hansson, F; Kilany, S; Milsom, I; Schiotz, HA; Svensson, M1
Kadekawa, K; Nishijima, S; Noguchi, K; Sugaya, K; Ueda, T; Yamamoto, H1
Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O1
Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M1
Inoue, M; Yokoyama, T1
Kociszewski, J; Poleszak, E; Serefko, A; Szopa, A; Wiśniewski, R; Woźniak, A; Wróbel, A1
Sahin, A; Urkmez, A; Yildirim, C; Yuksel, OH1
Brucker, BM; Charlson, ER; Enemchukwu, E; Howard, J; Jericevic, D; Krupp, L; Pape, D; Peyronnet, B; Rosenblum, N; Rude, T; Zhovtis-Ryerson, L1
El-Abd, AS; El-Abd, SA; Radwan, MH; Soliman, MG; Tawfik, AM1
Chae, C; Cheon, SH; Kim, SC; Kwon, T; Moon, KH; Park, M; Park, S; Yoon, JH1
Abou-Ramadan, AR; El-Abd, AS; El-Abd, S; El-Gamal, OM; Raheem, AA; Soliman, MG1
Chandna, A; Devana, SK; Kumar, S; Mete, UK; Parmar, KM; Sharma, AP; Singh, SK1
Gomes, T; Herschorn, S; Jarvi, K; Juurlink, D; Matta, R; Nam, RK1
Chen, SF; Chuang, YC; Kuo, HC; Liao, CH; Wang, CC1
Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B1
Abdelaziz, AS; Ghoneem, AM; Salama, NM1
Chess-Williams, R; McDermott, C; Sellers, DJ; West, EG1
Hsiao, SM; Lin, HH; Su, TC; Tu, FC; Wu, PC1
Liu, YQ; Tang, QL; Tao, RZ; Wu, J; Zhou, S1
Brubaker, L; Halverson, T; Mueller, ER; Wolfe, AJ1
Hara, H; Imamura, T; Ishizuka, O; Minagawa, T; Ogawa, T; Suzuki, A; Ueno, M1
Chang, SH; Chen, DY; Chen, HX; Chou, EC; Huang, CM; Huang, CP; Huang, PH; Lan, JL; Wu, PC; Yeo, KJ1
Hiren Prajapati, HP; Krunal Vishavadia, KV; Madhu Sharma, MS; Sandip Solanki, SS1
Azis, A; Ciayadi, TA; Hendarto, J; Kholis, K; Palinrungi, MA; Syahrir, S; Syarif, S1
Badrawy, M; Hasan, MA; Mohamed, AR; Nour, IM1

Reviews

5 review(s) available for solifenacin succinate and mirabegron

ArticleYear
The use of pharmacotherapy for male patients with urgency and stress incontinence.
    Current opinion in urology, 2014, Volume: 24, Issue:6

    Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urinary Incontinence, Urge; Urological Agents

2014
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Current medical research and opinion, 2016, Volume: 32, Issue:4

    Topics: Acetanilides; Administration, Oral; Adrenergic beta-Antagonists; Aged; Benzhydryl Compounds; Blood Pressure; Clinical Trials as Topic; Constipation; Female; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Retrospective Studies; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive

2016
[Comprehensive pharmacologic management of overactive bladder].
    Urologiia (Moscow, Russia : 1999), 2017, Issue:1

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Combinations; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive

2017
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    World journal of urology, 2018, Volume: 36, Issue:8

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents

2018
Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Neurourology and urodynamics, 2019, Volume: 38, Issue:1

    Topics: Acetanilides; Humans; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents

2019

Trials

34 trial(s) available for solifenacin succinate and mirabegron

ArticleYear
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    European urology, 2015, Volume: 67, Issue:3

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents

2015
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    BJU international, 2015, Volume: 116, Issue:4

    Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2015
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.
    Neurourology and urodynamics, 2016, Volume: 35, Issue:6

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents

2016
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
    Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:4

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Decision Support Techniques; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Risk Assessment; Risk Factors; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2016
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    European urology, 2016, Volume: 70, Issue:1

    Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents

2016
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    The Journal of urology, 2016, Volume: 196, Issue:3

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics; Young Adult

2016
Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Urologia internationalis, 2016, Volume: 97, Issue:3

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics

2016
Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
    Actas urologicas espanolas, 2016, Volume: 40, Issue:9

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2016
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYM
    World journal of urology, 2017, Volume: 35, Issue:5

    Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2017
Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Lower urinary tract symptoms, 2018, Volume: 10, Issue:2

    Topics: Acetanilides; Drug Substitution; Female; Humans; Long-Term Care; Postmenopause; Prospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2018
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    BJU international, 2017, Volume: 120, Issue:4

    Topics: Acetanilides; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Internationality; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Risk Assessment; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence

2017
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    International journal of clinical practice, 2017, Volume: 71, Issue:5

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2017
Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
    The patient, 2017, Volume: 10, Issue:6

    Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive; Urological Agents

2017
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Neurourology and urodynamics, 2018, Volume: 37, Issue:1

    Topics: Acetanilides; Double-Blind Method; Drug Therapy, Combination; Humans; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Visual Analog Scale

2018
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    European urology focus, 2017, Volume: 3, Issue:6

    Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents

2017
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.
    Blood pressure monitoring, 2018, Volume: 23, Issue:3

    Topics: Acetanilides; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles

2018
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    European urology, 2018, Volume: 74, Issue:4

    Topics: Acetanilides; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Symptom Assessment; Thiazoles; Time; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents

2018
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:3

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood Pressure; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Nasopharyngitis; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia

2019
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
    Neurourology and urodynamics, 2019, Volume: 38, Issue:2

    Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult

2019
Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?
    BioMed research international, 2019, Volume: 2019

    Topics: Acetanilides; Adult; Aged; Female; Humans; Lower Urinary Tract Symptoms; Middle Aged; Prospective Studies; Solifenacin Succinate; Suburethral Slings; Thiazoles

2019
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
    Lower urinary tract symptoms, 2020, Volume: 12, Issue:1

    Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2020
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    European urology, 2020, Volume: 77, Issue:1

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Databases, Factual; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive

2020
Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
    Acta medica Okayama, 2019, Volume: 73, Issue:5

    Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Middle Aged; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Visual Analog Scale

2019
Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
    Archivos espanoles de urologia, 2020, Volume: 73, Issue:1

    Topics: Acetanilides; Adult; Drug Therapy, Combination; Humans; Middle Aged; Quality of Life; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Catheters; Urological Agents

2020
Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
    Urology, 2020, Volume: 145

    Topics: Acetanilides; Adult; Constipation; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Patient Reported Outcome Measures; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2020
Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
    World journal of urology, 2021, Volume: 39, Issue:6

    Topics: Acetanilides; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Single-Blind Method; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2021
Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Urologia internationalis, 2021, Volume: 105, Issue:11-12

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Age Factors; Child; Child, Preschool; Egypt; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents

2021
Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial.
    Urologia, 2022, Volume: 89, Issue:4

    Topics: Acetanilides; Humans; Pain; Prospective Studies; Quality of Life; Solifenacin Succinate; Stents; Tamsulosin; Thiazoles; Treatment Outcome; Urological Agents

2022
Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:10

    Topics: Acetanilides; Aged; Aged, 80 and over; Central Nervous System Diseases; Cognition; Cohort Studies; Drug Therapy, Combination; Humans; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2022
Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms.
    World journal of urology, 2022, Volume: 40, Issue:8

    Topics: Acetanilides; Humans; Quality of Life; Solifenacin Succinate; Stents; Thiazoles; Treatment Outcome; Urological Agents

2022
Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial.
    Scientific reports, 2022, 08-20, Volume: 12, Issue:1

    Topics: Acetanilides; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Vascular Stiffness

2022
Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study.
    Scientific reports, 2022, 11-07, Volume: 12, Issue:1

    Topics: Acetanilides; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Prospective Studies; Quality of Life; Solifenacin Succinate; Stents; Treatment Outcome; Urinary Bladder, Overactive

2022
Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial.
    Lower urinary tract symptoms, 2023, Volume: 15, Issue:4

    Topics: Acetanilides; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Sjogren's Syndrome; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2023
A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms.
    The Pan African medical journal, 2023, Volume: 46

    Topics: Humans; Pain; Quality of Life; Solifenacin Succinate; Stents; Tadalafil; Urological Agents

2023

Other Studies

34 other study(ies) available for solifenacin succinate and mirabegron

ArticleYear
Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
    Urology, 2015, Volume: 85, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive

2015
Incontinence: Adding mirabegron to solifenacin improves patient outcomes.
    Nature reviews. Urology, 2016, Volume: 13, Issue:6

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence

2016
Re: A Randomized, Controlled Trial of Effectiveness and Safety of Management of OAB Symptoms in Elderly Men and Women with Standard-Dosed Combination of Solifenacin and Mirabegron.
    The Journal of urology, 2016, Volume: 195, Issue:6

    Topics: Acetanilides; Aged; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2016
Combined treatment with a β
    Neurourology and urodynamics, 2017, Volume: 36, Issue:4

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cold Temperature; Disease Models, Animal; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Inbred SHR; Solifenacin Succinate; Stress, Physiological; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents

2017
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    European urology, 2016, Volume: 70, Issue:5

    Topics: Acetanilides; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2016
Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
    The Journal of urology, 2017, Volume: 197, Issue:4

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2017
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE).
    The Journal of urology, 2017, Volume: 197, Issue:3 Pt 1

    Topics: Acetanilides; Double-Blind Method; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2017
Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.
    Neurourology and urodynamics, 2017, Volume: 36, Issue:7

    Topics: Acetanilides; Cholinergic Antagonists; Humans; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents

2017
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
    Urology, 2017, Volume: 104

    Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Catheterization; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Muscarinic Antagonists; Prostatic Diseases; Randomized Controlled Trials as Topic; Residual Volume; Risk; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents

2017
Evaluation of Maltose-Induced Chemical Degradation at the Interface of Bilayer Tablets.
    Chemical & pharmaceutical bulletin, 2017, Volume: 65, Issue:5

    Topics: Acetanilides; Drug Stability; Maltose; Molecular Structure; Solifenacin Succinate; Tablets; Thiazoles

2017
Incontinence: Patients prefer combination therapy.
    Nature reviews. Urology, 2017, Volume: 14, Issue:9

    Topics: Acetanilides; Double-Blind Method; Humans; Patient Reported Outcome Measures; Solifenacin Succinate; Thiazoles

2017
American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
    Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:6

    Topics: Acetanilides; Administration, Intranasal; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Deamino Arginine Vasopressin; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Hydrogels; Mitomycin; Multicenter Studies as Topic; Nocturia; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urology

2017
Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?
    BJU international, 2017, Volume: 120, Issue:4

    Topics: Acetanilides; Cholinergic Antagonists; Drug Therapy, Combination; Follow-Up Studies; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics

2017
Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
    The Canadian journal of urology, 2017, Volume: 24, Issue:6

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Antidiuretic Agents; Deamino Arginine Vasopressin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscarinic Antagonists; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urination

2017
Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    The journal of obstetrics and gynaecology research, 2018, Volume: 44, Issue:3

    Topics: Acetanilides; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Retrospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents

2018
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
    Urology, 2018, Volume: 117

    Topics: Acetanilides; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Databases as Topic; Drug Industry; Drug Prescriptions; Humans; Indoles; Medicare Part D; Practice Patterns, Physicians'; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents; Urology

2018
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:1 Pt 2

    Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2019
Combination Therapy for Overactive Bladder: Who Approves?
    European urology, 2018, Volume: 74, Issue:4

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2018
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eu
    European urology, 2019, Volume: 75, Issue:3

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2019
Re: Efficacy and Safety of Combinations of Mirabegron and Solifenacin Compared with Monotherapy and Placebo in Patients with Overactive Bladder (SYNERGY Study).
    The Journal of urology, 2018, Volume: 200, Issue:3

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2018
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients
    European urology, 2019, Volume: 75, Issue:3

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2019
Overactive bladder - pharmacological treatment.
    Revista da Associacao Medica Brasileira (1992), 2019, May-02, Volume: 65, Issue:4

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antidepressive Agents; Benzilates; Benzofurans; Brazil; Clinical Decision-Making; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Pyrrolidines; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive

2019
RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Neurourology and urodynamics, 2019, Volume: 38, Issue:6

    Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive

2019
A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
    Scandinavian journal of urology, 2019, Volume: 53, Issue:4

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Denmark; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Norway; Practice Patterns, Physicians'; Prospective Studies; Pyrrolidines; Registries; Solifenacin Succinate; Sweden; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive

2019
Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury.
    Lower urinary tract symptoms, 2020, Volume: 12, Issue:1

    Topics: Acetanilides; Animals; Disease Models, Animal; Female; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Spinal Cord Injuries; Thiazoles; Urethra; Urinary Bladder; Urological Agents

2020
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways.
    Pharmacology, biochemistry, and behavior, 2020, Volume: 189

    Topics: Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Duloxetine Hydrochloride; Female; Locomotion; Rats; Rats, Wistar; Signal Transduction; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2020
Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Investigative and clinical urology, 2021, Volume: 62, Issue:3

    Topics: Acetanilides; Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Male; Retrospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2021
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
    European urology focus, 2022, Volume: 8, Issue:5

    Topics: Aged; Canada; Case-Control Studies; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive

2022
Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database.
    Minerva urology and nephrology, 2022, Volume: 74, Issue:6

    Topics: Aged; Aged, 80 and over; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention

2022
Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.
    Scientific reports, 2022, 07-20, Volume: 12, Issue:1

    Topics: Acetanilides; Animals; Carbachol; Female; Mice; Muscarinic Antagonists; Solifenacin Succinate; Stress, Psychological; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2022
Urobiome changes differ based on OAB treatment in adult females.
    International urogynecology journal, 2023, Volume: 34, Issue:6

    Topics: Acetanilides; Adult; Drug Therapy, Combination; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence

2023
Cold stress-induced bladder overactivity in type 2 diabetic mellitus rats is mitigated by the combination of a M
    Lower urinary tract symptoms, 2023, Volume: 15, Issue:2

    Topics: Adrenergic Agonists; Adrenergic beta-3 Receptor Agonists; Animals; Cold-Shock Response; Diabetes Mellitus, Type 2; Female; Muscarinic Antagonists; Quality of Life; Rats; Receptors, Adrenergic; Receptors, Muscarinic; RNA, Messenger; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive

2023
[Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
    Urologiia (Moscow, Russia : 1999), 2023, Issue:2

    Topics: Acetanilides; Humans; Muscarinic Antagonists; Prescriptions; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents

2023
Fluorimetric study on a novel FDA-approved combination used for the treatment of overactive bladder syndrome in different matrices.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024, Feb-15, Volume: 307

    Topics: Drug Therapy, Combination; Fluorometry; Humans; Solifenacin Succinate; Time; Urinary Bladder, Overactive

2024